Enterprise Value
37.37M
Cash
40.72M
Avg Qtr Burn
-9.867M
Short % of Float
0.87%
Insider Ownership
0.19%
Institutional Own.
36.66%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Erivedge (vismodegib) Details BCC (Basal Cell Carcinoma) | Approved Quarterly sales | |
CA-4948 (emavusertib)+/- ibrutinib Details Non-Hodgkin lymphoma, Cancer, Blood cancer | Phase 1/2 Data readout | |
CA-4948 (emavusertib) Details Acute myeloid leukemia, Myelodysplastic syndrome, Blood cancer, Cancer | Phase 1/2 Data readout | |
Phase 1/2 Initiation | ||
CI-8993 (anti-VISTA antibody) Details Solid tumor/s, Cancer | Phase 1 Data readout |